Literature DB >> 29526356

[Standard or specific unit costs: Which criteria for choosing an economic evaluation of health strategies in multicentric studies?]

J Margier1, S Baffert2, A-G Le Corroller-Soriano3.   

Abstract

The question of what monetary value should be assigned to consumed resources, that is to say the choice of the unit cost, is a major consideration in terms of impact on the cost analysis results. To date, no agreement has been reached regarding this methodological question. The choices made by methodologists and the subsequent impact on the results of the analysis are only rarely put forward. This work addresses the theoretical framework of health strategy evaluations that can be carried out either in the normative framework of the conventional economic approach of well-being, referred to as welfarist, or in that of an approach referred to as extra-welfarist. It also provides elements that help clarify the choice of the hospital unit costs used to calculate the cost of health strategies, so as to reconcile the use of such studies and improve their comparability. What is preferable, opting for specific per hospital unit costs or applying a standard unit cost to all facilities? How should a standard cost be calculated? Is it appropriate to calculate an average of the unit costs, as recommended by certain guidelines? The advantages and the limitations of the various modes of assessing hospital resources in the setting of multicentric trials are discussed.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Keywords:  Cost; Coût; Evaluation; Guidelines; Hospital; Hôpital; Production; Recommandation; Technologie; Technology; Évaluation

Mesh:

Year:  2018        PMID: 29526356     DOI: 10.1016/j.respe.2018.02.002

Source DB:  PubMed          Journal:  Rev Epidemiol Sante Publique        ISSN: 0398-7620            Impact factor:   1.019


  1 in total

1.  "Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors".

Authors:  François Gernier; Djihane Ahmed-Lecheheb; Patricia Pautier; Anne Floquet; Cédric Nadeau; Sophie Frank; Jérôme Alexandre; Frédéric Selle; Dominique Berton-Rigaud; Elsa Kalbacher; Hubert Orfeuvre; Alain Lortholary; Paule Augereau; Fabien Labombarda; Lionel Perrier; Jean-Michel Grellard; Idlir Licaj; Bénédicte Clarisse; Aude-Marie Savoye; Héloise Bourien; Thibaut De La Motte Rouge; Jean-Emmanuel Kurtz; Katia Kerdja; Anaïs Lelaidier; Amandine Charreton; Isabelle Ray-Coquard; Florence Joly
Journal:  BMC Cancer       Date:  2021-10-26       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.